Managerial turnover is hitting Sarepta Therapeutics Inc. as the biotech company prepares to seek regulatory approval for its high-profile drug for a rare and fatal form of muscular dystrophy, according to people familiar with the matter.. On Thursday, Sarepta disclosed in a regulatory filing that it had fired its chief scientific officer, Arthur Krieg. People familiar with the matter said he was fired after raising concerns with members of Sarepta's board about Chief Executive Chris Garabedian's management of the company. As...
  